Kestra Holdings' recapitalization will provide additional fuel to an already robust growth engine, which includes industry-leading recruiting, a powerful service and technology platform, and a ...

February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

A major local cyber engineering firm has made a significant move to improve its capabilities in the realm of electromagnetic ...

JOTROL is designed to overcome the historical challenges of resveratrol by significantly enhancing bioavailability while minimizing gastrointestinal side effects. The upcoming Phase 2a trial will ...